



News Release

New indications for Advantix® Spot-on

Repellent's broad spectrum of activity enlarged even further

Leverkusen – Advantix® Spot-on has been given regulatory approval in Europe for the treatment of dogs to control two additional ectoparasites: the sandfly *Phlebotomus perniciosus* and the stable fly *Stomoxys calcitrans*. *Phlebotomus perniciosus* is the most important vector of leishmaniosis. The stable fly *Stomoxys calcitrans* can also transmit infectious diseases and is a very annoying blood-sucking fly that primarily attacks the ears of dogs. A single treatment with Advantix® Spot-on repels both insect species for three and four weeks respectively, thus preventing them from feeding on the treated dog.

In total, the spectrum of activity covered by Advantix® includes the major blood-feeding and disease-transmitting parasites in western and central Europe – fleas (*Ctenocephalides felis*), ticks (the Brown Dog tick *Rhipicephalus sanguineus*, the Castor Bean tick *Ixodes ricinus* and the Marsh tick *Dermacentor reticulatus*) and biting insects (the sandfly species *Phlebotomus papatasi* and *Phlebotomus perniciosus*, the mosquitoes *Aedes aegypti* and *Culex pipiens* and the stable fly *Stomoxys calcitrans*).

Advantix® contains a combination of two active ingredients: imidacloprid (10%) and permethrin (50%). It has a repellent action against ticks and mosquitoes and is also highly effective against fleas. Moreover, it is the only spot-on product in Europe, which is approved to repel and kill the Marsh tick *Dermacentor reticulatus*, the vector of canine babesiosis. Advantix® prevents parasites from biting and stinging, thus reducing the risk of transmission of pathogens causing infections



known as CVBD (canine vector-borne diseases). Relevant CVBD's are, for example, leishmaniosis, babesiosis, Lyme borreliosis and ehrlichiosis.

About Bayer HealthCare AG:

Bayer HealthCare, a subgroup of Bayer AG, is one of the world's leading innovative companies in the health care and medical products industry. In 2005, the Bayer HealthCare subgroup had sales of about €9.4 billion. Some 33,800 people are employed by Bayer HealthCare worldwide (Animal Health Division: approximately €56 million in sales and 3,000 employees).

The company combines the activities of the Animal Health, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals divisions. The Pharmaceuticals and Biological Products divisions were combined effective January 1, 2006. The new Pharmaceuticals Division comprises the Hematology/Cardiology, Oncology, and Primary Care business units.

Our aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. These products enhance well-being and quality of life by diagnosing, preventing and treating disease.

Leverkusen, July 10, 2006
(hb) (2006-07-327e)

Your Contact:

Dr. Hermann-Josef Baaken

Phone: +49 214 30 53366, Fax: +49 214 30 71640

E-mail: hermann-josef.baaken@bayerhealthcare.com

Just a click away – our online press service:

www.viva.vita.bayerhealthcare.com or for product information: www.advantix.info

Forward-Looking Statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.